Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of the bone morphogenetic protein (BMP) pathway in prostate cancer (PC) is unclear. This study aimed to characterize aspects of the BMP pathway in PC by assessing BMP2, Smad8, and Smad4 expression in normal, hyperplastic, and malignant prostate tissue, and to correlate findings with progression to PC. METHODS: Radical prostatectomy (RP) specimens from 74 patients with clinically localized PC (median follow‐up 51 months, range 15–152), 44 benign prostatic hypertrophy (BPH) lesions, and 4 normal prostates (NPs) were assessed for BMP2, Smad8, and Smad4 expression using immunohistochemistry. RESULTS: Both BMP2 (P < 0.001) and nuclear Smad4 (P < 0.0001) expression were significantly decreased in PC compared to benign prostate tissue. Nuclear Smad8 was present in normal/benign prostate tissue but absent in PC and adjacent hyperplasia. Furthermore, loss of BMP2 (P < 0.001) and decreased nuclear Smad4 (P = 0.05) expression correlated with increasing Gleason score. CONCLUSIONS: These data suggest that decreased BMP2, nuclear smad8 and nuclear Smad4 expression are associated with the progression to PC, and in particular loss of BMP2 and Smad4 are related to progression to a more aggressive phenotype. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma
Biankin, A. V., Morey, A. L., Lee, C.-S., Kench, J. G., Biankin, S. A., Hook, H. C., Head, D. R., Hugh, T. B., Sutherland, R. L., & Henshall, S. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.063 · Cited by 163 · cited 2×
“Smad4 was detected using a mouse monoclonal antibody with the HepG2 cell line as a positive control ( antibody) and MDA MB 468 breast cancer cell line as a negative control [22].”
MethodSelf-citation
Cited by
Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 526
Bone Morphogenetic Protein-2 in Development and Bone Homeostasis
Halloran, D., Durbano, H. W., & Nohe, A. (2020) · Journal of Developmental Biology · doi:10.3390/jdb8030019 · Cited by 348
Jenkins, B. J., Grail, D., Nheu, T., Najdovska, M., Wang, B., Waring, P., Inglese, M., McLoughlin, R. M., Jones, S. A., Topley, N., et al. (2005) · Nature Medicine · doi:10.1038/nm1282 · Cited by 308
Nuclear Receptor Coregulators and Human Disease
Lonard, D. M., Lanz, R. B., & O’Malley, B. W. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0012 · Cited by 302
Buijs, J. T., Rentsch, C. A., van der Horst, G., van Overveld, P. G. M., Wetterwald, A., Schwaninger, R., Henriquez, N. V., ten Dijke, P., Borovecki, F., Markwalder, R., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070168 · Cited by 200
Defective pulmonary vascular remodeling in Smad8 mutant mice
Huang, Z., Wang, D., Ihida-Stansbury, K., Jones, P. L., & Martin, J. F. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp214 · Cited by 81
McCarthy, A. J., & Chetty, R. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205095 · Cited by 71
Metadata
- Authors
- Horvath, L. G., Henshall, S. M., Kench, J. G., Turner, J. J., Golovsky, D., Brenner, P. C., O'Neill, G. F., Kooner, R., Stricker, P. D., Grygiel, J. J., & Sutherland, R. L.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2003-12-11
- Volume
- 59
- Issue
- 3
- Pages
- 234-242
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2025565204
- Cited by
- 114
- References
- 2
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.